These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 24672094)

  • 1. Clinical effects of rifaximin in patientswith hepatic encephalopathy intolerant or nonresponsive to previous lactulose treatment: An open-label, pilot study.
    Sama C; Morselli-Labate AM; Pianta P; Lambertini L; Berardi S; Martini G
    Curr Ther Res Clin Exp; 2004 Sep; 65(5):413-22. PubMed ID: 24672094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rifaximin treatment for reduction of risk of overt hepatic encephalopathy recurrence.
    Flamm SL
    Therap Adv Gastroenterol; 2011 May; 4(3):199-206. PubMed ID: 21694804
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of hepatic encephalopathy in the hospital.
    Leise MD; Poterucha JJ; Kamath PS; Kim WR
    Mayo Clin Proc; 2014 Feb; 89(2):241-53. PubMed ID: 24411831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacotherapy for hepatic encephalopathy.
    Phongsamran PV; Kim JW; Cupo Abbott J; Rosenblatt A
    Drugs; 2010 Jun; 70(9):1131-48. PubMed ID: 20518580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Rifaximin Plus Lactulose with the Lactulose Alone for the Treatment of Hepatic Encephalopathy.
    Ahire K; Sonawale A
    J Assoc Physicians India; 2017 Aug; 65(8):42-46. PubMed ID: 28799305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rifaximin for treatment of hepatic encephalopathy.
    Maclayton DO; Eaton-Maxwell A
    Ann Pharmacother; 2009 Jan; 43(1):77-84. PubMed ID: 19092143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of a specific
    Manzhalii E; Moyseyenko V; Kondratiuk V; Molochek N; Falalyeyeva T; Kobyliak N
    World J Hepatol; 2022 Mar; 14(3):634-646. PubMed ID: 35582294
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination therapy for the treatment and prevention of hepatic encephalopathy.
    Mohammad RA; Regal RE; Alaniz C
    Ann Pharmacother; 2012 Nov; 46(11):1559-63. PubMed ID: 23092866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rifaximin in the treatment of chronic hepatic encephalopathy.
    Puxeddu A; Quartini M; Massimetti A; Ferrieri A
    Curr Med Res Opin; 1995; 13(5):274-81. PubMed ID: 7555036
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RiMINI - the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial.
    Schulz C; Schütte K; Kropf S; Schmitt FC; Vasapolli R; Kliegis LM; Riegger A; Malfertheiner P
    Trials; 2016 Feb; 17(1):111. PubMed ID: 26926775
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-World Experience of the One-Year Efficacy of Rifaximin Add-On to Lactulose Is Superior to Lactulose Alone in Patients with Cirrhosis Complicated with Recurrent Hepatic Encephalopathy in Taiwan.
    Chang C; Huang CH; Tseng HJ; Yang FC; Chien RN
    J Pers Med; 2021 May; 11(6):. PubMed ID: 34071787
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study.
    Paik YH; Lee KS; Han KH; Song KH; Kim MH; Moon BS; Ahn SH; Lee SJ; Park HJ; Lee DK; Chon CY; Lee SI; Moon YM
    Yonsei Med J; 2005 Jun; 46(3):399-407. PubMed ID: 15988813
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Effect of Rifaximin with and without Lactulose on the Active Bacterial Assemblages in the Proximal Small Bowel and Faeces in Patients with Minimal Hepatic Encephalopathy.
    Schulz C; Schütte K; Vilchez-Vargas R; Vasapolli R; Malfertheiner P
    Dig Dis; 2019; 37(2):161-169. PubMed ID: 30428474
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy.
    Sharma BC; Sharma P; Lunia MK; Srivastava S; Goyal R; Sarin SK
    Am J Gastroenterol; 2013 Sep; 108(9):1458-63. PubMed ID: 23877348
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is rifaximin better than nonabsorbable disaccharides in hepatic encephalopathy?: A meta-analysis.
    Cheng J; Chen Y; Cao W; Zuo G
    Medicine (Baltimore); 2021 Dec; 100(51):e28232. PubMed ID: 34941089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Rifaximin Versus Placebo or Other Active Drugs in Critical ill Patients With Hepatic Encephalopathy.
    Han X; Luo Z; Wang W; Zheng P; Li T; Mei Z; Wang J
    Front Pharmacol; 2021; 12():696065. PubMed ID: 34690751
    [No Abstract]   [Full Text] [Related]  

  • 17. Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: a double-blind, randomized, dose-finding multi-centre study.
    Williams R; James OF; Warnes TW; Morgan MY
    Eur J Gastroenterol Hepatol; 2000 Feb; 12(2):203-8. PubMed ID: 10741936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of rifaximin in combination with lactulose in end-stage liver disease patients with MELD greater than 20: a single center experience.
    Mantry PS; Mehta A; Graydon R
    Transplant Proc; 2014 Dec; 46(10):3481-6. PubMed ID: 25498076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targets to improve quality of care for patients with hepatic encephalopathy: data from a multi-centre cohort.
    Bajaj JS; O'Leary JG; Tandon P; Wong F; Kamath PS; Biggins SW; Garcia-Tsao G; Lai J; Fallon MB; Thuluvath PJ; Vargas HE; Maliakkal B; Subramanian RM; Thacker LR; Reddy KR
    Aliment Pharmacol Ther; 2019 Jun; 49(12):1518-1527. PubMed ID: 31032966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Randomized Controlled Trial Comparing the Efficacy of a Combination of Rifaximin and Lactulose with Lactulose only in the Treatment of Overt Hepatic Encephalopathy.
    Hasan S; Datta S; Bhattacherjee S; Banik S; Saha S; Bandyopadhyay D
    J Assoc Physicians India; 2018 Jan; 66(1):32-6. PubMed ID: 30341842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.